Novel target and mab candidates for the treatment of hcmv infection

The present invention relates to a method for treating an infection, particularly HCMV infection. To date, there are very few reports on the role of DC-SIGN+ dendritic cells in very early phases of viral infections. By using four anti-human DC-SIGN monoclonal antibodies, the inventors have demonstrated that DC-SIGN might be considered as the most important receptor for both pre- and post-fusion HCMV gB on monocyte-derived dendritic cells (MDDCs). In particular, the invention relates to a method for treating an infection in a subject in need thereof comprising a step of administering to said subject an agent that blocks the interaction between DC-SIGN and an infectious ligand.

Keywords: Infectious Diseases, Antivirals, HCMV, DC-SIGN
Patent Application number: European Procedure (Patents) (EPA) - 23 Janv. 2017 - 17305064.2
Inventors:
HALARY FranckPIN Jean-JacquesRAZANAJAONA-DOLL Diane
Publications:
Org Biomol Chem. 2017 Sep 20;15(36):7660-7671. doi: 10.1039/c7ob01569k.

Reference:

BIO16304-T1

    Business Developper
    contact
    Elodie Acloque
    Business Developer
    Patent filling date: 23-01-2017
    Rare disease: No
    Second indication: No

    You might also be interested in